Recent developments in hepatitis C antiviral research 1999 - 2000

Abstract

The exponential increase in the number of publications related to hepatitis C antiviral research both from academia and the pharmaceutical industry in recent years highlights the intense interest in combating this pathogen. The number of people infected with hepatitis C virus (HCV) (4 million in the US, nearly 200 million worldwide), as well as the poor tolerability and disappointing efficacy of IFN-based treatments make obvious the need for improved therapeutic options. Promising advances have been made, including the advent of improved IFN-based treatments as well as a small number of early clinical trials of novel therapies. Perhaps the most positive development has been the disclosure of what may finally be a reproducible, logistically feasible cell-based HCV RNA replication and expression system. It continues to remain highly likely, however, that a number of potent and specific drugs against HCV will ultimately be required in order to effectively combat HCV infection.

• antisense oligonucleotides
• CD81 receptor
• DNA vaccines
• helicase
• IFN-alpha
• IFN sensitivity determining region
• internal ribosome entry site
• non-structural proteins
• protease
• ribavirin
• ribozymes
• RNA-dependent RNA polymerase
• subgenomic replicons